Radiation therapy is an alternative for the treatment of early prostate
cancer, and is often used in the treatment of regionally advanced prostate cancer.
Hoag Family Cancer Institute’s radiation oncology program is another
example of its commitment to excellence in personalized prostate cancer
treatment. The entire first floor of the cancer institute is dedicated
to radiation oncology, where its highly specialized team of medical experts
delivers the latest in state-of-the-art radiation therapy to patients.
The most progressive options available for prostate cancer patients include
the use of seed-implant brachytherapy. For patients with more advanced
prostate cancer, and sometimes as an adjunct to surgery, image guided
IMRT using VMAT or tomotherapy is available.
SpaceOAR® hydrogel is the first FDA cleared spacing device to protect
the rectum in men undergoing radiation therapy for prostate cancer. Hoag
is the first hospital in Southern California, and west of Mississippi,
to offer this revolutionary product.
Hoag’s radiation oncology program offers a full spectrum of leading-edge
radiation treatment options. Visit us for a complete list of
radiation oncology services.
Surgery is a vital component in the successful treatment of prostate cancer.
Hoag Family Cancer Institute medical team includes experienced surgeons
and the latest techniques and technology in the surgical management of
Increasingly, prostatectomies are being performed via robot-assisted laparoscopy
to minimize the extent of the surgery. Hoag surgeons utilize the da Vinci®
Si HD™ Surgical System to perform robotic minimally invasive radical
prostatectomy. Technological advantages, which include a high-definition
optical magnification system and endo-wrist capability, afford a post-operative
recovery during which patients experience less pain, less blood loss and
quicker return to normal activities. Other potential benefits may include
a faster return of urinary continence and sexual function.
Jeffrey Yoshida, M.D., Hoag Urologic Cancer Program Director and fellowship-trained
urologic surgeon, is an expert in robotic surgery and has performed more
than 1,000 robotic prostatectomies.
The superior care provided to Hoag prostate cancer patients is most clearly
illustrated by having a relative five-year survival rate of 100 percent
since the early 1990s.
Hoag was a leader in the use of prostate specific antigen to screen for
prostate cancer. This is one of the reasons that more than 90 percent
of Hoag prostate cancer patients have only localized disease at the time
a diagnosis of prostate cancer is made.
Treatment of Metastatic Disease
Although it is uncommon to detect metastatic prostate cancer at the time
of diagnosis, many men eventually develop metastatic prostate cancer,
typically in the bones.
Hormonal therapy is usually effective initially, and systemic chemotherapy
is typically used in patients who develop hormone-refractory prostate
cancer. Increasingly, local therapies are being used to eliminate certain
sites of metastatic prostate cancer.
For patients with small numbers of metastases to the liver, surgical resection,
radiofrequency ablation, cryoablation and tomotherapy are all treatment
options, in addition to systemic therapy or intrahepatic chemotherapy.
Isolated lung metastases may be treated by surgical resection, preferably
video-assisted thoracic surgery, radiofrequency ablation, cryoablation
or radiation therapy. Bone metastases are typically treated with radiation
therapy, whereas brain metastases can usually be effectively treated by
With the availability of all these treatment options, the outlook for patients
with metastatic cancer is more hopeful than ever.
Multidisciplinary Urologic Cancer Case Conferences
Hoag's multidisciplinary urologic oncology cancer case conferences
provide collaborative care planning for prostate cancer patients. This
twice-monthly cancer case conference brings together a multidisciplinary
team of prostate cancer specialists, including urologists, medical oncologists,
radiation oncologists, radiologists, pathologists, nurses and support staff.